Posted by Squiggles on February 26, 2007, at 18:00:31
In reply to Re: Drug manufacturing and quality control, posted by notfred on February 26, 2007, at 11:27:39
Whenever I come across seminars of this type,
I feel as if I am spying.:-) It's pretty "inner-circle stuff", but it certainly gives you an idea of how and what decisions are made by the Government in the development, evaluation and decision-making process of how to treat the mentally ill population.This is a pdf file:
"UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH, NAT'L. INSTITUTE OF MENTAL HEALTH:
In the matter of:
FDA NIMH MATRICS Workshop on Clinical Trial Designs for Neurocognitive Drugs for Schizophrenia.
Neuroscience Center, Conf. Rm. C, 6001 Executive Blvd., Rockville, MD, Fri., April 23, 2004.
---------------------
What I find fascinating about this workshop, is the long-term search for appropriate antipsychotics targeted specifically at cognitive disabilities in schizophrenia. It seems to me that it is already assumed that cognitive disabilities in mental illness are neurologically specific. What I mean by that, it does not seem to be an option in the research, that affective maladies, as in manic-depression, can very well distort cognitive ability. Moreover, the search for drugs to stabilize neurocognitive states is imperative in the FDA. It sounds like the government wants the mentally ill to *appear* OK, with the new drugs, even though they do not feel OK.
Squiggles
poster:Squiggles
thread:735309
URL: http://www.dr-bob.org/babble/20070224/msgs/736535.html